Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 9;10(10):1226.
doi: 10.3390/antibiotics10101226.

Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies

Jean Gibb  1 , Darren W Wong  1
Affiliations
Review

Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies

Jean Gibb et al. Antibiotics (Basel). .

Abstract

Stenotrophomonas maltophilia is an urgent global threat due to its increasing incidence and intrinsic antibiotic resistance. Antibiotic development has focused on carbapenem-resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter, with approved antibiotics in recent years having limited activity for Stenotrophomonas. Accordingly, novel treatment strategies for Stenotrophomonas are desperately needed. We conducted a systemic literature review and offer recommendations based on current evidence for a treatment strategy of Stenotrophomonas infection.

Keywords: Stenotrophomonas; Stenotrophomonas maltophilia; avibactam; aztreonam; cefiderocol; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest to disclose.

References

    1. Falagas M.E., Kastoris A.C., Vouloumanou E.K., Dimopoulos G. Community-acquired Stenotrophomonas maltophilia infections: A systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 2009;28:719–730. doi: 10.1007/s10096-009-0709-5. - DOI - PubMed
    1. Brooke J.S. Advances in the microbiology of Stenotrophomonas maltophilia. Clin. Microbiol. Rev. 2021;34:e00030-19. doi: 10.1128/CMR.00030-19. - DOI - PMC - PubMed
    1. Falagas M.E., Kastoris A.C., Vouloumanou E.K., Rafailidis P.I., Kapaskelis A.M., Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: A systematic review of the literature. Futur. Microbiol. 2009;4:1103–1109. doi: 10.2217/fmb.09.84. - DOI - PubMed
    1. Mojica M.F., Rutter J.D., Taracila M., Abriata L.A., Fouts D.E., Papp-Wallace K.M., Walsh T.J., LiPuma J.J., Vila A.J., Bonomo R.A. Population structure, molecular epidemiology, and β-lactamase diversity among Stenotrophomonas maltophilia isolates in the United States. mBio. 2019;10:e00405-19. doi: 10.1128/mBio.00405-19. - DOI - PMC - PubMed
    1. Biagi M., Vialichka A., Jurkovic M., Wu T., Shajee A., Lee M., Patel S., Mendes R.E., Wenzler E. Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 2020;64:e00559-20. doi: 10.1128/AAC.00559-20. - DOI - PMC - PubMed

LinkOut - more resources